QLT Announces Results of Annual Meeting of Shareholders
January 12 2016 - 7:00AM
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) (“QLT” or the “Company”) is
pleased to announce that, on a vote by ballot, the six incumbent
directors of the Company were re-elected at the Company’s annual
general meeting held on January 8, 2016 (the “Meeting”).
Detailed results of the vote for the election of
directors are as follows:
Nominee |
Votes For |
% |
Votes Withheld |
% |
Jason M. Aryeh |
30,993,845 |
90.32 |
3,321,352 |
9.68 |
Dr. Geoffrey F. Cox, Ph.D |
31,208,904 |
90.95 |
3,106,293 |
9.05 |
Dr. John W. Kozarich, Ph.D |
31,223,945 |
90.99 |
3,091,252 |
9.01 |
Jeffrey A. Meckler |
30,811,599 |
89.79 |
3,503,598 |
10.21 |
Dr. Stephen L. Sabba, M.D. |
31,202,781 |
90.93 |
3,112,416 |
9.07 |
John C. Thomas, Jr. |
30,971,911 |
90.26 |
3,343,286 |
9.74 |
Final voting results on all matters voted on at
the Meeting will be filed on SEDAR at www.sedar.com and EDGAR
at www.sec.gov.
About QLTQLT is a biotechnology
company dedicated to the development and commercialization of
innovative ocular products that address the unmet medical needs of
patients and clinicians worldwide. We are focused on developing our
synthetic retinoid program for the treatment of certain inherited
retinal diseases.
QLT’s head office is based in Vancouver, Canada
and the Company is publicly traded on NASDAQ Stock Market (symbol:
QLTI) and the Toronto Stock Exchange (symbol: QLT). For more
information about the Company’s products and developments, please
visit our web site at www.qltinc.com.
QLT Inc. Contacts:
For Investors:
Andrea Rabney or David Pitts
Argot Partners
P: 212-600-1902
andrea@argotpartners.com
david@argotpartners.com
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Apr 2023 to Apr 2024